Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

10.1016/j.lanwpc.2021.100276

Saved in:

Bibliographic Details
Main Authors:	Wang, Bei, Goh, Yun Shan, Fong, Siew-Wai, Young, Barnaby Edward, Ngoh, Eve Zi Xian, Chavatte, Jean-Marc, Salleh, Siti Nazihah Mohd, Yeo, Nicholas Kim-Wah, Amrun, Siti Naqiah, Hor, Pei Xiang, Loh, Chiew Yee, Lee, Chia Yin, Chan, Yi-Hao, Chang, Zi Wei, Tay, Matthew Zirui, Rouers, Angeline, Torres-Ruesta, Anthony, Carissimo, Guillaume, Soh, Mun Kuen, Lee, Raphael Tze Chuen, Xu, Yani, Pada, Surinder, Lin, Raymond Tzer Pin, Leo, Yee-Sin, Lye, David C., Maurer-Stroh, Sebastian, Ng, Lisa F. P., Renia, Laurent, Wang, Cheng-, I
Other Authors:	BIOLOGICAL SCIENCES
Format:	Note
Published:	Elsevier Ltd 2022
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/233634
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
by: Renia, Laurent, et al.
Published: (2022)

Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB
by: Chang, Zi Wei, et al.
Published: (2023)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
by: Renia, Laurent, et al.
Published: (2023)

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
by: Goh, Yun Shan, et al.
Published: (2023)

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
by: Goh, Yun Shan, et al.
Published: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Lim, Xin Rong, et al.
Published: (2021)

Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern
by: Low, Jia Ming, et al.
Published: (2023)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Rebecca P. Payne, et al.
Published: (2022)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Mansanguan S.
Published: (2023)

Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age
by: Tan, Sharon H. X., et al.
Published: (2023)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
by: Lim, Xin Rong, et al.
Published: (2023)

Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients
by: Tan, Eunice X, et al.
Published: (2023)

Clinical course, immunogenicity, and efficacy of BNT162b2 mRNA vaccination against SARS-CoV-2 infection in liver transplant recipients
by: Tan, Eunice X., et al.
Published: (2024)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
by: Pimchanok Kulsirichawaroj, et al.
Published: (2022)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
by: Kulsirichawaroj P.
Published: (2023)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Chantasrisawad N.
Published: (2023)

Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing
by: Siripipattanamongkol N.
Published: (2023)

Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech)
by: Lin, Weiqin, et al.
Published: (2022)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
by: Low, Jia Ming, et al.
Published: (2021)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Niyomnaitham S.
Published: (2023)

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
by: Chia, Wan Ni, et al.
Published: (2023)

Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
by: Low, Jia Ming, et al.
Published: (2023)

BNT162b2 vaccination induces SARS-CoV-2 specific antibody secretion into human milk with minimal transfer of vaccine mRNA
by: Low, Jia Ming, et al.
Published: (2023)

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study
by: Yung, Chee Fu, et al.
Published: (2024)

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
by: Yung, Chee Fu, et al.
Published: (2023)

Robust sars?cov?2 antibody responses in asian covid?naïve subjects 180 days after two doses of bnt162b2 mrna covid?19 vaccine
by: Lau, Chin-Shern, et al.
Published: (2022)

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
by: Chantasrisawad N.
Published: (2023)

BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study
by: Lim, Xin Rong, et al.
Published: (2023)

Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection
by: Tay, Matthew Zirui, et al.
Published: (2022)

Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection
by: Tay, Matthew Zirui, et al.
Published: (2022)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac<sup>®</sup>, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
by: Chatsiricharoenkul S.
Published: (2023)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
by: Niyomnaitham S.
Published: (2023)

Modification of cultural heritage elicits disgust : the role of cultural essence, identification and sacredness of cultural heritage
by: Lim, Jonathan Zi Kai
Published: (2018)

Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5–11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial
by: Wittawatmongkol O.
Published: (2023)

Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave
by: Goh, Yun Shan, et al.
Published: (2024)

Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
by: Fong, Siew-Wai, et al.
Published: (2023)

We Forum, vol xiii No. 162 - Feb. 8, 1990
by: Burgos, Jr., Jose
Published: (1990)

Outbreak response management of a COVID-19 patient diagnosed on an open ward in Singapore
by: Pada, Surinder Kaur
Published: (2021)